Laporan Laba Rugi (TTM)
Laporan Laba Rugi Radiopharm Theranostics Limited - Equity Warrant menunjukkan perubahan pendapatan dan pengeluaran selama periode waktu tertentu. Data Laporan Laba Rugi meliputi Penjualan dan Pendapatan, Laba Kotor, Penelitian dan Pengembangan (R&D), Beban Penjualan, Umum dan Administrasi (SG&A), Laba Operasi, Beban Pajak Penghasilan, Beban Bunga, Pendapatan Non-Operasi, Laba per Saham (EPS), dan Saham yang Beredar.
Semua angka adalah kelipatan 1,000,000 kecuali unit per saham.
|
2022 09-30 |
2022 12-31 |
2023 03-31 |
2023 06-30 |
2023 09-30 |
2023 12-31 |
2024 03-31 |
2024 06-30 |
2024 09-30 |
2024 12-31 |
2025 03-31 |
2025 06-30 |
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 4 | 5 | 6 | 6 | 6 | 4 | 2 | 1 | 0 | 7 | 13 |
| Change (%) | 100.00 | 22.85 | 18.60 | -1.58 | -1.61 | -33.71 | -50.86 | -41.56 | -71.11 | 1,976.50 | 95.18 | |
| % of Revenue | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 | 100.00 |
| Cost Of Sales | 10 | 13 | 16 | 20 | 23 | 26 | 24 | 22 | 22 | 22 | 13 | 4 |
| Change (%) | 27.64 | 23.95 | 19.32 | 17.01 | 14.53 | -8.72 | -9.56 | 0.25 | 0.25 | -41.72 | -71.60 | |
| % of Revenue | 485.53 | 309.86 | 312.63 | 314.53 | 373.93 | 435.29 | 599.39 | 1,103.25 | 1,892.52 | 6,567.87 | 184.32 | 26.82 |
| Gross Operating Profit | -8 | -9 | -11 | -13 | -17 | -20 | -20 | -20 | -21 | -21 | -6 | 10 |
| Change (%) | 8.87 | 24.47 | 19.66 | 25.67 | 20.43 | -1.27 | -1.29 | 4.42 | 4.23 | -72.93 | -269.39 | |
| % of Revenue | -385.53 | -209.86 | -212.63 | -214.53 | -273.93 | -335.29 | -499.39 | -1,003.25 | -1,792.52 | -6,467.87 | -84.32 | 73.18 |
| SG&A | 13 | 14 | 15 | 15 | 16 | 16 | 16 | 16 | 15 | 15 | 16 | 17 |
| Change (%) | 5.04 | 5.49 | 5.21 | 3.86 | 3.72 | -2.33 | -2.39 | -3.18 | -3.28 | 6.30 | 5.93 | |
| % of Revenue | 614.67 | 322.81 | 277.19 | 245.88 | 259.48 | 273.52 | 403.01 | 800.57 | 1,326.34 | 4,440.77 | 227.34 | 123.38 |
| R&D | 14 | 28 | ||||||||||
| Change (%) | 100.00 | |||||||||||
| % of Revenue | 200.39 | 205.33 | ||||||||||
| OpEx | 23 | 27 | 31 | 35 | 39 | 43 | 40 | 37 | 37 | 36 | 42 | 48 |
| Change (%) | 15.01 | 14.53 | 12.69 | 11.24 | 10.10 | -6.26 | -6.68 | -1.19 | -1.21 | 15.45 | 13.38 | |
| % of Revenue | 1,100.20 | 632.67 | 589.82 | 560.41 | 633.41 | 708.80 | 1,002.40 | 1,903.82 | 3,218.85 | 11,008.64 | 612.05 | 355.53 |
| Operating Income | -21 | -23 | -26 | -29 | -33 | -37 | -36 | -35 | -36 | -36 | -35 | -34 |
| Change (%) | 6.51 | 12.97 | 11.48 | 14.02 | 12.30 | -1.75 | -1.78 | 1.05 | 1.03 | -2.53 | -2.60 | |
| % of Revenue | -1,000.20 | -532.67 | -489.82 | -460.41 | -533.41 | -608.80 | -902.40 | -1,803.82 | -3,118.85 | -10,908.64 | -512.05 | -255.53 |
| Interest Expense | -5 | -1 | -1 | -0 | -0 | -1 | -1 | -1 | -0 | -0 | ||
| Change (%) | -75.08 | -31.24 | -90.59 | 490.75 | -2.88 | -2.96 | -44.61 | -80.54 | ||||
| % of Revenue | -250.61 | -31.22 | -17.48 | -1.39 | -2.73 | -32.83 | -54.55 | -183.26 | -4.89 | -0.49 | ||
| Net Income | -28 | -26 | -30 | -35 | -40 | -46 | -46 | -48 | -45 | -43 | -40 | -37 |
| Change (%) | -8.64 | 17.65 | 15.00 | 16.06 | 13.84 | 1.24 | 3.57 | -5.16 | -5.44 | -6.06 | -9.14 | |
| % of Revenue | -1,314.02 | -600.25 | -574.81 | -557.36 | -657.30 | -760.50 | -1,161.52 | -2,448.23 | -3,973.17 | -13,006.38 | -588.39 | -273.90 |
Source: Capital IQ
